The Catalyst

Most Recent Posts

08.30.12

A strong U.S. biopharma industry is vital to ensuring the health of our nation's economy and citizens. Investment in R&D supports jobs within a variety of U.S. industries. The below infographic explains how only with a strong and growing biopharma sector can we add jobs, reduce long term healthcare costs and prolong the quality of life for all Americans.

08.30.12 | By Kaelan Hollon

Erin Mullen wrote a great post about lessons learned in Hurricane Andrew, and stopped by my office yesterday to talk about what's been going on with Rx Response in light of Hurricane Isaac this week.

08.29.12 | By Jennifer Wall

I've read many interesting Forbes.com blog posts by John LaMattina, formerly the president of Pfizer R&D, but today's post a

08.27.12 | By Jennifer Wall

For nearly 30 years, PhRMA has held an annual awards event called the Discoverer's Award to honor pioneers in the biopharmaceutical industry whose discoveries helped move the goal post forward in the war against disease. Past recipients were honored for discovering breakthrough medicines for diseases such as cervical cancer, depression, diabetes and HIV/AIDS.

08.27.12 | By Scott LaGanga

Earlier this month, I traveled to China to meet with public and private sector officials working to address the global counterfeit drug epidemic.

08.24.12

Yesterday, I highlighted a nice video produced by PhRMA on the prescription drug life cycle. Today, I'd like to talk a bit more about the prescription drug life cycle concept portrayed in that video - a concept with which many people are unfamiliar.

08.24.12 | By Kaelan Hollon

If you haven't had a chance to see Eli Lilly's CEO Dr. John Lechleiter speak, I strongly encourage it. Dr. Lechleiter is a wonky, funny and brilliant former chemist who is a passionate stalwart on the issue of counterfeit drugs.

08.24.12 | By Erin Mullen

...that I was huddled in an interior bathroom in South Florida with my fiance, my sister's roommate and two golden retrievers. We had the radio tuned to hear local meteorologist Bryan Norcross' voice through the dark hours, but it wasn't loud enough to drown out the howling wind and random thumps and crashes against the house.

08.23.12

"Understanding the prescription drug life cycle and how it should affect public policy." That sounds like the title of an obscure 2:00pm, four cup of coffee on a Friday afternoon industry seminar.

08.23.12 | By Kaelan Hollon

As Washington Post's Lenny Bernstein notes in today's Wellness column, schools are starting to get serious about addressing childhood obesity. And it's about time, since obesity is one of the most insidious problems in health care.

08.22.12

The quest for a cure can be a rigorous process that is laden with a series of setbacks and failures. Fortunately, researchers use what they learn from each of these setbacks to advance the science one step closer to a breakthrough.

08.21.12

We often talk around here about the rising rates of chronic diseases (see here, here and the Partnership here) such as diabetes. Sadly, over four thousand Americans are diagnosed with diabetes each and every day.

08.21.12

As part of our "From Hope to Cures" guest blog series, today we have a post from Gary A.

08.20.12

When we first launched this blog, we made a promise to host an open and ongoing conversation about the role innovative medicines play in battling disease and reducing health care costs.

08.16.12 | By Greg Lopes

There is a great article in the latest issue of Health Affairs that demonstrates yet again that properly adhering to prescribed treatments not only improves our health, but saves money. The Harvard and Express Scripts researchers looked at diabetes patients over three years and found that improved adherence to diabetes medications reduced the odds of a subsequent hospitalization or emergency department visit by 13 percent.

Pages